Tag
FDA Approval
3 articles
Precision Neuroscience Raises $250M as Surface BCI Bets Against Neuralink's Invasive Model
Bill Ackman's $42.5M bet on less invasive brain implants signals capital's turn away from single-neuron precision toward infection risk reduction and faster FDA approval paths.
Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
The biotech reported 60% year-over-year revenue growth in Q2 2026 on gMG and CIDP therapies, with Wall Street's consensus target at $1,180.25.
Revolution Medicines' Rasonque Doubles Pancreatic Cancer Survival
Approval of the once-daily pill, which extended median survival from 6.7 months to 13 months in late-stage trials, values the company at $46 billion as it targets a previously untreatable protein mutation.